Hormonal
Reduction of SirT1 expression in adipose tissue causes macrophage recruitment and inflammation, while maintaining or increasing SirT1 levels prevents this inflammation.
In obesity, SirT1 levels in fat drop, which triggers inflammation and immune cell buildup. Restoring normal SirT1 levels (e.g., through caloric restriction or weight loss) helps prevent this. However, artificially boosting SirT1 in lean individuals might not help and could potentially cause issues, so natural regulation via energy balance is key.
We found that inducible or genetic reduction of SirT1 in vivo causes macrophage recruitment to adipose tissue, whereas overexpression of SirT1 prevents adipose tissue macrophage accumulation caused by chronic high-fat feeding.
Why this rating
Strong evidence from multiple models (ASO knockdown, knockout, transgenic overexpression) and human cohort correlations, though human data is observational.
Source
SirT1 Regulates Adipose Tissue Inflammation
Matthew P. Gillum et al. · Diabetes · 2011
DOI 10.2337/db11-0616
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →